Resistance and partial responses to targeted monotherapy are major obstacles in cancer treatment. Systematic approaches to identify effi cacious drug combinations for cancer are not well established, especially in the context of genotype. To address this, we have tested pairwise combinations of an array of small-molecule inhibitors on early-passage melanoma cultures using combinatorial drug screening. Results reveal several inhibitor combinations effective for melanomas with activating RAS or BRAF mutations, including mutant BRAF melanomas with intrinsic or acquired resistance to vemurafenib. Inhibition of both EGF receptor and AKT sensitized treatmentresistant BRAF mutant melanoma cultures to vemurafenib. Melanomas with RAS mutations were more resistant to combination therapies relative to BRAF mutants, but were sensitive to combinations of statins and cyclin-dependent kinase inhibitors in vitro and in vivo . These results show the use of combinatorial drug screening for discovering unique treatment regimens that overcome resistance phenotypes of mutant BRAF-and RAS -driven melanomas.
INTRODUCTION
Inhibition of oncogenic drivers by targeted agents improves patient response rates ( 1-3 ), but primary and secondary resistance to these drugs is common (4) (5) (6) . In melanoma, about half of patients harbor activating mutations in the BRAF oncogene ( 7 ) . Most of these patients respond to the mutant BRAF inhibitor vemurafenib (PLX4032); however, some patients have primary resistance to therapy ( 8, 9 ) . Acquired resistance occurs over a period of months in nearly all patients who do respond ( 8, 9 ) . A large number of resistance mechanisms have been identifi ed (10) (11) (12) (13) (14) (15) (16) (17) (18) , and combinatorial therapies with vemurafenib will be needed to prevent disease progression and improve survival of patients.
Another roadblock to progress in melanoma therapeutics is the lack of effective therapies for mutant RAS -driven melanomas, which are found in up to one fi fth of patients with melanoma ( 7 , 19 ) . RAS mutations in general ( NRAS , KRAS , and HRAS ) occur in up to a third of all human cancers ( 20 ) and are associated with relatively poorer prognoses in many cancer types, including lung and melanoma ( 21, 22 ) . Furthermore, activating mutations in NRAS are one mechanism for secondary (acquired) vemurafenib resistance in a subset of mutant BRAF melanomas ( 14 ) . Thus, an urgent need has arisen to identify effective drug combinations that attack mutant RAS -driven tumors and prevent treatment resistance. To date, no reports have described any systematic method for identifying the most effective drug combinations for either mutant RAS or BRAF melanomas. Therefore, we have used a combinatorial high-throughput drug screening (cHTS) approach to evaluate the selectivity of drugs, alone and in pairs, in the context of BRAF -or RAS-activating mutations, using early-passage melanoma cultures.
We identify several unique cytotoxic combinations with agents commonly used in the clinic that have pronounced genotype selectivity for RAS mutant or BRAF mutant melanomas, including those with primary and acquired resistance to vemurafenib. Furthermore, we confi rm the effectiveness of select combinations in vitro and in vivo and provide mechanistic reasoning for their cooperation. The results show that combinatorial drug screening illuminates positive drug interactions in melanoma otherwise obscured with single-agent screening alone, and that these fi ndings may guide the implementation of new combinatorial drug trials. 
RESULTS
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BRAF , RAS , or those wild-type for both (hereafter, WT ; Supplementary Table S2 ). Concentration-response curves generally exhibited sigmoidal or exponential behavior and many agents elicited incomplete growth inhibition ( Supplementary  Fig. S1A ), suggesting that additional agents are needed for full growth inhibition. Concentrations required to inhibit 50% of cell growth (GI 50 ) were variable among cell lines (Supplementary Table S3 ). Compounds arrayed in duplicate on different plates yielded similar concentration-dependent responses ( Supplementary Fig. S1B ), as did compounds in related pharmacologic classes ( Supplementary Fig. S1C ).
Unsupervised clustering of single-agent effi cacies (maximal growth inhibition achieved) was conducted to identify agents that selectively inhibit growth of genotypic subsets. Drugs were partitioned into 3 clusters, including agents lacking effect ( Fig. 1A , Cluster 1), agents with uniform high effi cacy (Cluster 2), and agents with variable effi cacies across cell lines (Cluster 3). Reclustering of drugs showing variable effi cacies confi rmed mutant BRAF selectivity of vemurafenib, PLX4720, and GDC-0879 as well as clustering of other agents belonging to the same specifi c classes, including ErbB, SRC/ ABL, and mitogen-activated protein kinase kinase (MEK) inhibitors ( Fig. 1B ). In agreement with previous studies, growth-stimulatory effects of vemurafenib were seen in some mutant RAS and WT melanomas, and incomplete growth inhibition was observed for all mutant BRAF lines at concentrations up to 10 μmol/L vemurafenib ( Fig. 1C ; refs. 23, 24 ) . Approximately 25% of mutant BRAF cultures were innately resistant to vemurafenib, showing a GI 50 beyond 3 μmol/L ( Fig. 1D ) , as observed elsewhere ( 25 ) . It has been suggested that PTEN defi ciency may hinder vemurafenibinduced apoptosis ( 16 ) , whereas co-occurring PTEN and RB1 defi ciency may attenuate growth inhibition by vemurafenib ( 18 ) . Although we did not evaluate the contribution of apoptosis to growth inhibition in the limited number of lines defi cient in PTEN (YUGEN8, YUMUT, and YUKADI) or RB1 (YUSAC2), we observed growth inhibition resistance to vemurafenib in the setting of normal PTEN and RB1 expression ( Fig. 1E ; Supplementary Table S2), suggesting that loss of either or both is not essential for primary vemurafenib resistance. Indeed, others have observed that primary resistance to vemurafenib can occur by alternative mechanisms, including increased MET/hepatocyte growth factor receptor (HGFR) signaling ( 26, 27 ) .
We found that other drugs eliciting selectively higher growth inhibition in mutant BRAF melanomas included the SRC/ABL inhibitor bosutinib, the fi broblast growth factor receptor (FGFR) inhibitor dovitinib and the EGF receptor (EGFR) inhibitor gefi tinib ( Supplementary Fig. S1D ). No drugs were selective exclusively for the WT melanomas, likely owing to the greater genetic heterogeneity of this group. MEK inhibitors U0126 and CIP-1374 were selective as single agents for both the mutant BRAF and RAS groups ( Supplementary  Fig. S1D ), but were more effective for mutant BRAF lines. Lines with primary resistance to vemurafenib were also less sensitive to MEK blockade ( Fig. 1B ) , in agreement with other reports ( 28 ) . Interestingly, the 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase) inhibitor simvastatin, which indirectly interferes with posttranslational processing of RAS proteins ( 29 ) , was the only drug to show a trend toward a higher degree of growth inhibition in the mutant RAS group ( Fig. 1F ) . Collectively, these data reveal a limited number of single agents with genotype-selective effi cacy (Supplementary Table S4 ). Moreover, unless used at high concentrations (10 μmol/L or greater), these single agents inhibited cell growth incompletely, which likely refl ects that these agents are incompletely cytotoxic at lower concentrations.
Combinatorial Drug Screening
The limited responses to single agents prompted us to determine whether more defi ned genotype-selective patterns and higher effi cacies could be observed using cHTS. Forty representative agents with high or variable effi cacies ( Fig. 1A , Clusters 2 and 3) were chosen for cHTS (Supplementary Table S5) . As a group, these agents inhibit many of the signaling pathways important in cancer ( Supplementary Fig. S2A ). As melanoma lines varied in their sensitivities to each agent, we chose 3 consensus concentrations based on corrected median values for the GI 50 , GI 25 , and GI 10 effect levels across all melanoma lines (Supplementary Fig. S2B ), together giving 9 pairwise combinations per drug pair. Nineteen melanoma lines, including 8 mutant BRAF , 6 mutant RAS (5 NRAS mutants and 1 HRAS mutant), and 5 WT lines, were screened against more than 7,000 pairwise combinations in parallel with single-agent controls.
Relationships between genotype and drug combination effi cacy were fi rst assessed by unsupervised clustering of the most effective combination of the 9 tested for each drug pair per cell line ( Fig. 2A ) . Two clusters are apparent, with one dominated by mutant BRAF melanomas that are sensitive to a substantial number of combinations, and the other dominated by mutant RAS and WT melanomas, which were generally less sensitive to the combinations. To ascertain genotypeselective combinations, we fi ltered data for drug pairings that yielded an average 15% or greater growth inhibition exclusively in a genotypic group. Mutant BRAF -selective drug pairs greatly outnumbered drug pairs selective for mutant RAS or WT groups (1,021; 75; and 22 combinations, respectively). Agents most frequently paired in combinations selective for the mutant BRAF group ("sensitizers") included the FGFR inhibitor PD173074, the pan-BCL2 family inhibitor obatoclax, vemurafenib, bosutinib, the c-MET inhibitor Pha665752, the ErbB inhibitor lapatinib, and the AKT inhibitor MK-2206 ( Fig. 2B ) . All of these agents were selective for BRAF mutant cultures at multiple concentration combinations (Supplementary Table S6 ), reinforcing their cooperative effect. Vemurafenib was not the most frequent sensitizer, possibly because of the lower concentrations used in combination screening (Supplementary Table S5 ) as well as the presence of 2 innately vemurafenib-resistant lines used in the screens (YUKSI and 501Mel, Fig. 1D ). At the concentrations tested in cHTS, none of these sensitizers were exclusively selective for mutant BRAF melanomas in single-agent screening.
Strikingly, 52% of mutant RAS -selective drug combinations involved simvastatin ( Fig. 2C ) , the only agent with a lower median GI 50 in the mutant RAS group in single-agent screening ( Fig. 1F ) . Despite the low number of mutant RASselective combinations, 25 other drugs paired with simvastatin showed greater effectiveness in the mutant RAS group, whereas only 4 drugs in combination with simvastatin were more effective in mutant BRAF lines, and were all general RESEARCH ARTICLE sensitizers of this group (Supplementary Table S7 ). Sixty-two of 64 combinations that elicited more than 50% inhibition in the mutant RAS group included simvastatin (Supplementary Table S8 ). Agents that combined with simvastatin at different concentrations selective for the mutant RAS group included the X-linked inhibitor of apoptosis protein (XIAP) inhibitor embelin, the novel allosteric MEK inhibitor CIP-1374, the insulin-like growth factor I receptor (IGF-IR) nonspecifi c inhibitor BMS-536924, the HSP90 inhibitor 17-desmethoxy-17-N , N -dimethylaminoethylaminogeldanamycin (17-DMAG), and the pan-cyclin-dependent kinase (CDK) inhibitor fl avopiridol (Supplementary Table S6 ). None of these agents showed greater potency exclusively in the mutant RAS group with single-agent screening ( Fig. 1B ; Supplementary Table S4) .
Finally, no drug combination partners were selective for the WT group of melanomas. Some combinations were effective (≥GI 75 ) for all genotypic groups, although many included compounds that have not been used in the clinic, or were tested at higher concentrations of clinically tested agents shown to be genotype selective in combinations. Supplementary Table S8 collectively lists the genotype-selective and -nonselective combinations.
Synergistic and Cytotoxic Drug Interactions in Mutant BRAF and RAS Melanomas
Drug combinations were analyzed for additive, synergistic, or antagonistic interactions. Single-agent effects assessed in cHTS were plotted in relation to theoretical combinatorial effects using the Bliss independence model ( 30 ) and to their measured effects for each of the 9 concentration combinations per drug pair, depicted globally as drug "interaction signatures" ( Fig. 3A ) . The majority of mutant BRAF melanomas shared a pattern of extensive synergies, whereas combinations in mutant RAS lines were more often antagonistic (i.e., less effective than predicted additivity; Fig. 3B ). To identify genotypeselective synergistic drug pairs, we conducted unsupervised Varying levels of effi cacy are seen across melanomas. BRAF V600E-targeting drugs vemurafenib, PLX4720, and GDC0879, marked in red, were effective in many mutant BRAF melanomas, yet less effective in others (yellow box). Black boxes surrounding compound names are those with shared targets that grouped together when clustered. C, Concentration-effect curves fi tted to median growth inhibition values for vemurafenib in the mutant BRAF , mutant RAS , and WT genotypic groups. Bracket indicates the concentration range of significant differences in drug potency; ***, P < 0.0001, Kruskal-Wallis test. D, comparison of vemurafenib concentrations required to induce 50% GI 50 in mutant BRAF melanoma lines. Red datapoints indicate cell lines with primary resistance to vemurafenib and extant PTEN. Green datapoints mark sensitive lines with PTEN homozygous deletion. E, PTEN and RB1 protein status confi rming no association with vemurafenib resistance in these lines. F, concentration-effect curves of median growth inhibition values for simvastatin in the 3 genotypic groups. A trend in higher potency of the drug in mutant RAS lines was observed (2-10 μmol/L). 
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clustering of average synergy values obtained from the 9 concentration combinations for each drug pair. Drugs that frequently appeared in combinations showing signifi cantly higher synergies included lapatinib, vemurafenib, bosutinib, nilotinib, and PD173074 ( Fig. 3C ), and were usually observed in BRAF mutant melanomas. In contrast, these combinations were often antagonistic in mutant RAS melanomas ( Fig. 3D ) . Lapatinib was the most frequent synergizing partner showing specifi city for mutant BRAF lines ( Fig. 3E ) .
A signifi cant number of patients with BRAF -mutated melanoma do not respond to vemurafenib ( 9 ) . YUKSI and 501Mel cell lines harbor activating BRAF mutations but show primary resistance to vemurafenib ( Fig. 1D ). These lines also showed higher relative resistance against many drugs paired with vemurafenib, even at the highest concentrations tested ( Fig. 3F ) . Nevertheless, both resistant lines were more sensitive to the same set of combinations that were effective for vemurafenib-sensitive melanomas, including vemurafenib paired with bosutinib, lapatinib, obatoclax, PD173074, or Pha665752 ( Fig. 3F , highlighted area) . Combinations that overlapped in our queries for highest average synergy and average effi cacy specifi c to mutant BRAF lines often included lapatinib and MK-2206 (summarized in Table 1 ). This fi nding suggests a shared mechanistic susceptibility in BRAF mutants to inhibition of the targets of these agents, regardless of vemurafenib sensitivity. MK-2206 and lapatinib were not found to be selective for mutant BRAF melanomas in single-agent screens, indicating that the genotype selectivity of these agents in combination, as based on BRAF or RAS mutation status, was not predictable by single-drug screening alone. Combinations most selective for RAS -mutated melanomas were mainly additive and included simvastatin with the pan-CDK inhibitor fl avopiridol or the HSP90 inhibitor 17-DMAG.
We next confi rmed cytotoxic and synergistic properties of select drug pairs that overlapped in our analyses for highest average synergy and effi cacy ( Table 1 ) . For mutant BRAFspecifi c combinations, we chose the AKT inhibitor MK-2206 paired with lapatinib or bosutinib ( of the 9 concentration combinations tested for each cell line (columns) for each unique drug pair (rows). Partitioning of mutant BRAF cultures (Cluster 1) and mutant RAS or WT melanoma cultures (Cluster 2) is readily apparent. B, frequency of agents that in pairwise combinations elicit a GI 25 or higher effect level and 15% or more growth inhibition in the mutant BRAF group relative to the other 2 groups. C, as in B but for mutant RAS melanomas. cell line representing all combinatorial data compiled in a 40 by 40 drug matrix. Inset at bottom: magnifi ed view of the 9 concentration combinations for a representative drug pair within its drug interaction matrix, to indicate scale. Yellow bar is the Bliss independent sum of growth inhibition for single agents; red indicates synergy, and green, antagonism (see also Supplementary Fig. S3A-S3C) . B, compilation of the total number of drug pair synergies, additivities, and antagonisms. P values calculated by χ 2 test. P < 0.05 for BRAF versus RAS for number of synergies and RAS versus BRAF or WT for number of antagonisms. C, unsupervised hierarchical clustering of average synergy values obtained from the 9 concentration combinations tested for each drug pair (rows) for each melanoma line (columns), and D, average antagonisms of the 9 combinations. Only drug pairs showing signifi cant differences are shown. E, frequencies of drugs appearing in mutant BRAF -selective combinations yielding signifi cantly higher relative average synergies. Lapatinib showed the largest number of synergies specifi c to mutant BRAF melanomas. F, percent growth inhibition of mutant BRAF lines treated with vemurafenib combined with other agents at maximal concentrations tested (see Supplementary Table S5 ). YUKSI (red), the line most intrinsically resistant to vemurafenib, was also less sensitive to these combinations. The second-most vemurafenib-resistant line 501Mel (black) used in cHTS was also less sensitive to many combinations. The most vemurafenib-sensitive line YULAC (green) was most sensitive to combinations with vemurafenib in almost all cases. Yellow highlight marks vemurafenib combinations that showed increased growth inhibition in the vemurafenib-resistant lines. G, drug combinations excluding vemurafenib, which showed highest selectivity toward mutant BRAF melanomas, were with lapatinib and the AKT inhibitor MK-2206. YUKSI and 501Mel were also sensitive to these combinations. Bars indicate means. Indicated P values calculated by Kruskal-Wallis ANOVA. Post hoc Fisher t test showed P < 0.05 for the mutant BRAF group versus the other groups. H, drug combinations with the highest effi cacy and selectivity toward RAS mutant melanomas included simvastatin with fl avopiridol. using a broader range of concentrations than those in cHTS confirmed the overall synergistic nature of these drug interactions, as determined by combination index calculations ( Fig. 4A ; Supplementary Table S9 ). Lapatinib or bosutinib in combination with MK-2206 was highly synergistic on the representative mutant BRAF line YUMAC. Simvastatin with flavopiridol or 17-DMAG was also additive on the mutant NRAS line YUGASP at high concentrations, but synergistic at concentrations well below the range used in cHTS. Lapatinib and MK-2206 individually induced approximately 20% cell death each (normalized to vehicle control) by 3 days in the BRAF mutant line YUMAC ( Fig. 4B and C ) . The combination of these 2 drugs at the same concentrations increased cell death by 50% (87% actual, 36% Bliss model prediction), consistent with their synergy seen in cHTS and isolobologram analyses. These agents alone or in combination lacked appreciable cytotoxicity in the mutant NRAS line YUGASP. Conversely, simvastatin paired with fl avopiridol was more cytotoxic in YUGASP (80% actual, 63% predicted), compared with the BRAF mutant line YUMAC (36% actual, 35% predicted). The combination of simvastatin with 17-DMAG, or bosutinib with MK-2206, similarly resulted in genotype-selective cytotoxicity in the mutant RAS and BRAF lines, respectively ( Fig. 4C; Supplementary Fig. S3F ). The genotype-unbiased combination of vorinostat and fl avopiridol was also cytotoxic to both RAS and BRAF lines at high concentrations. 
Most target classes were represented by only one compound in cHTS, so we verifi ed that the genotype-selective effects produced by these combinations are related to their target classes. The EGFR inhibitors gefi tinib or afatinib/ BIBW2992 paired with the AKT inhibitors MK-2206 or GSK692094 produced similar combination responses to lapatinib and MK-2206, and were more effective in mutant BRAF lines, including the line most intrinsically resistant to vemurafenib (YUKSI; Fig. 4D ; Supplementary Fig. S4A) . Likewise, the combination of statins, including lovastatin and atorvastatin, combined with the pan-CDK inhibitors fl avopiridol and AT7519 produced similar responses that were somewhat effective in mutant BRAF lines, but more effective in NRAS mutant and HRAS mutant lines ( Fig. 4D ;  Supplementary Fig. S4B ).
Vemurafenib-Resistant Mutant BRAF Cells Regain Sensitization to Vemurafenib upon Concomitant Inhibition of EGFR and AKT
We further evaluated the effi cacy of the lapatinib/MK-2206 combination with fl ow cytometry, clonogenic assays, and soft agar assays on mutant BRAF melanomas sensitive or resistant to vemurafenib, using repeated administration of lower concentrations of these agents to minimize off-target effects (see Methods). This treatment strategy was minimally effective for patient-derived lines with the greatest primary resistance to vemurafenib, including YUKSI and YUKOLI, as indicated by maintained cell viability and colony numbers with reduced colony size ( Fig. 5A and B ) , but relatively more effective for the vemurafenib-sensitive lines, including YULAC (Supplementary Fig. S5A ). Vemurafenib-resistant cell lines selected from YULAC and YUCOT lines ( Supplementary Fig. S5B ), hereafter, YULAC-R and YUCOT-R, respectively, were also less sensitive to this regimen ( Fig. 5B ; Supplementary Fig. S5C ). At 500 nmol/L and above, lapatinib and MK-2206 effectively suppressed their targets p-EGFR and p-AKT, respectively ( Fig.  5C ), despite moderate impact on viability and clonogenicity of these agents singly and in combination.
We next assessed the interaction of vemurafenib with lapatinib or MK-2206. Dual combination of vemurafenib with either of these agents moderately increased effi cacy relative to single-agent treatments in primary-resistant lines YUKSI and YUKOLI ( Fig. 5D and E ) and in acquired-resistant lines YULAC-R and YUCOT-R ( Fig. 5E ; Supplementary Fig. S5D and S5E). Vemurafenib and MK-2206 together were more effective in acquired-resistant lines; however, the triple combination of lapatinib, MK-2206, and vemurafenib greatly enhanced cytotoxicity and abolished colony growth in both primary and secondary resistance settings. Importantly, the dual and triple combinations did not induce substantial cytotoxicity in the mutant NRAS line YUGASP and only moderately reduced colony formation (Supplementary Fig. S5F ).
Receptor tyrosine kinase (RTK) activation often contributes to vemurafenib resistance in mutant BRAF melanomas ( 13, 14, 26, 27 ) . In primary vemurafenib-resistant YUKSI and YUKOLI BRAF mutant melanoma cells, inhibition of AKT with MK-2206 single-agent treatment effectively suppressed p-AKT but increased levels of p-EGFR and p-ERK by 24 hours ( Fig. 5C and F ; Supplementary Fig. S6A and S6B ). Conversely, vemurafenib or lapatinib alone did not change p-AKT levels in these lines. In the triple combinations, the activity of MAPK and phosphoinositide 3-kinase (PI3K)/mTOR complex (mTORC) pathways was effectively suppressed, as suggested by a strong reduction in p-ERK, p-AKT, and p-P70S6K ( Fig.  5F ), although some rescue of p-ERK signal was observed. This rescue was likely due to cross-pathway activation of ERK upon p-AKT inhibition with MK-2206, as all dual and triple combinations with MK-2206 partially restored p-EGFR and p-ERK.
The impact of these agents on MAPK and PI3K signaling in acquired vemurafenib-resistant lines (YULAC-R and YUCOT-R) was similar to that in primary vemurafenib-resistant lines. Vemurafenib or MK-2206 alone depleted or partially restored p-ERK levels, respectively ( Fig. 5G ; Supplementary Fig. S6C ). In contrast, single-agent lapatinib treatment in acquired vemurafenib-resistant lines resulted in initial suppression, but subsequent elevation of p-ERK and p-AKT levels relative to baseline ( Fig. 5G ) , whereas it had little impact on p-AKT and p-ERK in primary vemurafenib-resistant lines. Nevertheless, the 3 combined agents effectively suppressed both p-AKT and p-ERK levels in the vemurafenib-sensitive ( Supplementary Fig. S6D and S6E) and vemurafenib-resistant lines tested.
Finally, we assessed the single-, dual-, and triple-agent treatments in preventing the long-term emergence of resistant colonies ( Fig. 5H ) . As expected, the parental line YULAC readily formed colonies with lapatinib or MK-2206 alone or combined (data not shown). Dual-agent combinations with vemurafenib performed more effectively; however, a lower number of resistant clones did emerge. Only the vemurafenib/lapatinib/MK-2206 triple combination was found to impede the emergence of resistant colonies completely.
Mechanistic and In Vivo Evaluation of the Mutant NRAS -Selective Simvastatin/Flavopiridol Combination
Statins interfere with isoprenyl RAS modifi cations required for plasma membrane localization and activity (32) (33) (34) . Indeed, membrane localization of NRAS was nearly eliminated with simvastatin treatment ( Fig. 6A ) , confi rming an association between loss of membrane-anchored NRAS and induction of cytotoxicity. Still, a large number of other proteins, including cancer-relevant RAC and RHO proteins, are also isoprenylated and may be concomitantly affected by statins. We therefore carried out RNA interference (RNAi)-mediated knockdown experiments to compare the effects of NRAS reduction with statin-induced NRAS inhibition. NRAS siRNA treatments resulted in nearly complete loss of mutant NRAS protein, greatly reduced p-ERK, and moderately reduced p-AKT in mutant NRAS YUGASP cells ( Fig. 6B ) . The combination of NRAS siRNA and fl avopiridol treatment fully suppressed p-ERK levels and substantially increased BIM and PARP cleavage by 96 hours. This fi nding was associated with increased cytotoxicity relative to either treatment alone, as measured by fl ow cytometry ( Fig. 6C ) . As with NRAS siRNA, repeated administration of lower concentration simvastatin reduced activity of the MAPK and PI3K pathways. This effect was enhanced in the presence of fl avopiridol in NRAS mutant and HRAS mutant lines ( Fig. 6D ; Supplementary Fig. S7A and S7B), along with a signifi cant reduction in viability and clonogenicity ( Fig. 6E ; Supplementary Fig. S7C and S7D) . Fig. S7E  and S7F) . Collectively, these data show enhanced effects of statins combined with CDK inhibitors in NRAS mutant or HRAS mutant melanomas that may, in part, be mediated by reduction of NRAS activity.
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Finally, we tested the impact of the simvastatin/fl avopiridol combination in reducing tumor growth, using a preclinical xenograft model. YUGASP cells were injected subcutaneously into immunocompromised mice, and a dose-escalation study was conducted to ensure tolerability up to predefi ned maximum doses of the 2 drugs combined. No toxicity was observed with single agents or dual agents in the ranges of doses tested (data not shown). Simvastatin and fl avopiridol modestly reduced tumor growth as single agents, with fl avopiridol having a greater effect ( Fig. 6F and G ) . The combination of simvastatin and fl avopiridol signifi cantly reduced tumor growth and resulted in initial tumor regression within the fi rst week of treatment. The combination was well tolerated (Supplementary Fig. S7G ), and histologic assessment at the 2-week mark indicated a trend toward increased cell death, as indicated by pyknotic cell index and reduced mitotic index in the combination treatment group relative to the single-agent and mock treatment arms (Supplementary Fig. S7H ).
DISCUSSION
Resistance to therapies in cancer is a major clinical hurdle, creating a compelling need to discover more effective combinations of agents that are currently available. We present results from a drug combinatorial screen designed to probe positive drug interactions in mutation-defi ned subgroups of cancer. This screen has identifi ed previously undescribed drug interaction patterns and several combinations with potential for high effi cacy in melanoma ( Table 1 ) . Among these, statins with CDK inhibitors were validated as selective for NRAS and HRAS mutants, and a triple combination consisting of vemurafenib, EGFR, and AKT inhibitors was selective for BRAF mutant lines, including those with primary or in vitro -selected resistance to vemurafenib. 
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In patient-derived BRAF mutant melanomas with vemurafenib resistance, the EGFR inhibitors gefi tinib, lapatinib, and afatinib were minimally cytotoxic when used alone, as were the AKT inhibitors MK-2206 and GSK692094, but more effective when combined at high concentrations than at lower concentrations. Yet, combinations of lapatinib and MK-2206 at reduced concentrations still effectively sensitized resistant cells to vemurafenib, giving credence to the idea that the major targets of these agents are critical mediators of vemurafenib resistance.
Cross-pathway feedback control between the MAPK and PI3K pathways is an important feature of many cancers ( 35, 36 ) . In all vemurafenib-sensitive or -resistant BRAF mutant lines tested, we found an increase in ERK activity upon AKT inhibition with MK-2206. These effects were robust enough in primary vemurafenib-resistant lines to partially rescue p-ERK levels in spite of vemurafenib treatment. Thus, the consequences of MK-2206 treatment are likely 2-pronged: suppression of the survival role of the AKT pathway and alteration of feedback inhibition resulting in increased MAPK signaling, potentially through receptor kinases.
Melanomas with primary vemurafenib resistance were found to have higher baseline EGFR levels, similar to those in colorectal cancers insensitive to this agent ( 37, 38 ) . In contrast to these studies, we found that combined EGFR and mutant BRAF inhibition was not effective for primary vemurafenibresistant melanoma cells, or in preventing the emergence of resistant clones in vemurafenib-sensitive cells. Previous work in breast cancer showed upregulation of multiple RTKs, including EGFR, upon AKT inhibition with MK-2206 ( 36 ) . Thus, it is plausible that primary-resistant melanomas will require AKT inhibition as a prerequisite for enhancing reliance upon MAPK signaling through RTKs and mutant BRAF. In addition, the partial reduction in p-ERK with EGFR inhibition seen in these cells may increase sensitivity to further MAPK inhibition by vemurafenib treatment. More generally, this idea suggests that combinations of specifi c RTK inhibitors with AKT inhibitors could likewise resensitize acquired vemurafenib-resistant lines to vemurafenib, and indeed, we found Figure 6 . (Continued) D, Western blot for p-ERK and p-AKT levels after treatment with simvastatin, fl avopiridol, or both in mutant NRAS cells. The dual-agent combination reduced p-ERK and p-AKT levels more effectively than single agents. E, YUGASP cells were treated with simvastatin at 1 μmol/L, fl avopiridol at 0.1 μmol/L, or the combination. Viability (left) and clonogenicity (right) assessed by fl ow cytometry and 2D clonogenic assay, respectively. F, tumor weights of xenografted tumors grown in immunocompromised mice and treated with simvastatin, fl avopiridol, or both, or mock-treated with drug vehicle for 2 weeks. Kruskal-Wallis 1 way ANOVA, P < 0.0001; Asterisks over brackets indicate signifi cant differences between 2 treatment groups. **, P < 0.001; ***, P < 0.0001, by Dunn multiple comparison test. G, tumor volume over time plot for those treatments as in F . ***, P < 0.001 by 1-way ANOVA followed by Bonferroni multiple comparison test for endpoint tumor volumes. All pairwise group comparisons showed signifi cant differences, with the exception of mock-treated versus simvastatin alone. qod, every other day. 
that the triple-agent combination was superior in these cases. Moreover, this regimen also blocked the long-term development of resistant clones in parental vemurafenibsensitive cells, suggesting a route for prevention of vemurafenib resistance, which otherwise develops over a period of months ( 8, 9 ) .
The effects of the vemurafenib/lapatinib/MK-2206 combination were minor on mutant NRAS cells, reaffi rming its selectivity for lines with BRAF mutations. Generally, RAS mutant melanomas were resistant to most single-agent and dual-agent treatments in comparison with mutant BRAF melanomas and melanomas with WT BRAF and RAS , which is consistent with the slightly poorer clinical prognosis associated with NRAS mutation ( 22 ) . Many drug combinations that were synergistic in mutant BRAF cells tested in cHTS, including RTK inhibitor combinations, were more often antagonistic in mutant RAS cells. This fi nding likely refl ects the greater pleiotropy of RAS-dependent signaling, as RAS activates a variety of effector pathways, including MAPK, JAK-STAT, RAL-GDS, and PI3K signaling ( 20 , 34 ) .
Mutant RAS -selective combinations detected in cHTS often involved the HMG-CoA reductase inhibitor simvastatin. Clinical studies have not supported use of statins as cancer monotherapies ( 39 ) , and epidemiologic studies have not conclusively substantiated reduced cancer risk in individuals chronically treated with statins at the somewhat lower concentrations used for hypercholesterolemia control ( 39, 40 ) . Still, it remains to be seen if statins are more functional for the specifi c prevention or treatment of RAS mutant cancers.
Here, we fi nd that the impact of statins on NRAS mutant melanomas may be mediated through direct interference with the function of NRAS, as we confi rmed that it is relocalized from the plasma membrane under these conditions, an important component of RAS signaling ( 41 ) . Moreover, NRAS knockdown yielded biologic phenotypes similar to those with statin treatment, both alone and in combination with fl avopiridol. Nonetheless, NRAS knockdown was more effective in suppression of p-ERK than was simvastatin; and it is possible that the myriad proteins reliant on isoprenoid modifi cations-including additional GTP-binding proteins important in cancer, such as RAC and RHO-and more global effects on lipid metabolism contribute to these differences.
Concentrations of statins used in combinations to elicit complete cytotoxicity were by themselves only partially cytotoxic. Moreover, tumor growth inhibition with simvastatin alone in preclinical xenografts was not remarkable. RNAimediated knockdown of oncogenic NRAS elicited only partial cytotoxicity, similar to results seen with KRAS mutant cancers and mutant NRAS melanomas with or without activating BRAF mutations ( 14 , 42-44 ) . However, cHTS identifi ed multiple second agents combined with simvastatin that were more effective in mutant RAS melanomas. Thus, these data show that loss of mutant NRAS , whether induced by smallmolecule agents or by synthetic oligonucleotides, is mainly a critical priming event for cytotoxicity induced by a second agent such as an HSP90, MEK, or CDK inhibitor.
The pan-CDK inhibitor fl avopiridol alone was not selective for mutant RAS melanomas, so this drug in combination with statins presumably works to forestall residual cell-cycle activation through RAS-dependent pathways or through pathways acting in parallel ( 45 ) . In support of this idea, synthetic lethality has been shown elsewhere with combinatorial knockdown of mutant KRAS and CDK4 in non-small cell lung cancer mouse models ( 46 ) . One phase II trial of fl avopiridol as monotherapy in patients with stage IV melanoma resulted in stable disease in approximately half of patients, for up to half a year or more ( 47 ) . Candidate oncogenic drivers were not evaluated, and so the effi cacy of CDK inhibition in conjunction with oncogenic driver blockade, such as mutant RAS , remains unknown in humans. Our in vivo mouse studies show the tolerability and enhanced effi cacy of fl avopiridol in combination with sim vastatin for mutant NRAS melanoma. This combination may also prove superior for preventing or treating vemurafenib-resistant BRAF V600* melanomas that acquire de novo mutations in RAS ( 14 , 48 ) .
Over the past 2 decades, the discovery of novel targeted agents that inhibit the oncogenic drivers of cancers has paved the way for more favorable patient outcomes and, importantly, more tolerable therapies. However, even the most precisely targeted therapies when used alone are limited in their ability to promote cytotoxicity in some cancer cells ( 30 ) . Cancers associated with poor prognoses, such as advanced-stage melanomas, will require combination therapies to obstruct the outgrowth of resistant cells ( 49 ) . Combinatorial drug screening has allowed for the discovery and experimental confi rmation of a number of effective combination regimens that in the correct genotypic setting may prove more effective and tolerable in patients while avoiding selection for resistance through inadequate dosing.
METHODS
Melanoma Cell Cultures
Patient-derived melanoma lines, with the exception of 501Mel, were collected as previously described ( 24 ) . Cell lines were derived directly from human melanoma metastases using a Yale Institutional Review Board-approved protocol with informed consent. Tumor lines were further confi rmed by expression profi ling and Sanger sequencing for BRAF and NRAS mutational status (Supplementary  Table S2 ) and compared with the independent clinical genetic evaluation of the pathologic resection specimens in many cases. These studies served to validate that the short-term cultures expressed melanoma markers and were of the correct designated genotype. Cell lines were cultured in basal medium [OptiMEM (Invitrogen) supplemented with 10% FBS and 1% penicillin/streptomycin (P/S)] and maintained in a 37°C incubator maintained at 5% CO 2 . Acquired vemurafenib-resistant lines (YUCOT-R and YULAC-R) were generated by exposing parental lines to 3 μmol/L vemurafenib every 2 days for approximately 10 to 12 weeks.
Single-and Dual-Agent Screening
Cells were deposited into 384-well microtiter plates at 750 cells per well using a multidrop dispenser (Thermo) in 20 μL basal medium. Drug stock plates for 1,000× single agents were created by serial 1:2 dilution, typically from 10 mmol/L (Supplementary Table  S1 ), using an expandable multichannel pipette (MatrixTechCorp). A PlateMate Plus automated instrument (MatrixTechCorp) was used for pin transfer of 20 nL drug volume from drug stock plates into 384-well microtiter cell plates. A total of 0.1% and 20% DMSO was used as negative and positive controls, respectively. For dual-agent screens, 96-deep well plates were used for single-agent concentration stocks, and pairwise combinations of drugs were generated on July 1, 2017. © 2013 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from RESEARCH ARTICLE using hit-picking automation (Freedom EVO, Tecan). Each of 780 unique drug pairs at 9 concentration combinations was generated spanning twenty-two 384-well microtiter stock plates. All experiments were carried out in triplicate at the Yale Center for Molecular Discovery (YCMD, New Haven, CT). Cells were exposed to drug for 72 hours, followed by growth inhibition measurement with the CellTiter-Glo ATP detection assay (Promega) based on amenability for HTS ( 50 ) . Only experiments with high Z -factor quality indices (>0.5) were analyzed.
Statistical Analyses
Data were compiled into a relational database using PostgreSQL RDBMS (PostgreSQL.org). Statistics were computed with built-in functions of PostgreSQL or with R (R-project; http://www.r-project.org). In single-agent studies, concentration-effect curves were computed using Michaelis-Menten or 4-parameter logistic curve fi tting in R. GI values were only interpolated. Maximum GI and GI 50 effects achieved with single agents were hierarchically clustered by the Ward method based on Euclidean distance using R. The Kruskal-Wallis test was used to compare genotype groups with regard to effi cacy differences. For dual-agent effi cacy, unsupervised hierarchical clustering was conducted with heatmap.2 function from the gplots library in R. For synergy and antagonism studies, unsupervised clustering was conducted and analyzed by ANOVA and Tukey-Kramer pairwise testing. Identifi cation of drug synergy was assessed with the Bliss independence model ( 30 ) or the Chou-Talalay method ( 31 ) using normalized isobologram analyses.
Flow Cytometry
Cells were plated at 1 × 10 5 cells per well in 6-well format and allowed to adhere overnight. Lifted cells were combined with adherent cells harvested by trypsinization. Repeated administration of agents was conducted every other day for 3 total treatments using fresh medium and drugs, and analyzed by fl ow cytometry the following day. Cells were stained using the BD Pharmingen Apoptosis Detection Kit II according to the manufacturer's protocol (BD). Samples were analyzed with the BD LSRII fl ow cytometer, with recording of at least 10,000 events per sample. Cells were analyzed by doublet discrimination, and compensation was applied for each experiment. Each line was treated independently, and gates were fi xed based on negative control signals. Plots were generated using FlowJo 7.6.5.
Immunofl uorescence
Cells were plated on 8-chamber culture slides (BD Falcon) at 1,000 cells per well and allowed to adhere overnight before drug treatments. Cells were fi xed using 4% paraformaldehyde at room temperature for 15 minutes, followed by quenching with 100 mmol/L glycine and permeabilization with 0.1% Triton X-100/PBS, and blocked with 5% bovine serum albumin (BSA)/phosphate-buffered saline with Tween 20 (PBST) for 30 minutes at 37°C. The anti-NRAS antibody (Santa Cruz Biotechnology; clone F155), which recognizes both mutant and WT NRAS, was used at 1:100 in 100 μL blocking buffer overnight at 4°C, followed by Alexa Fluor 594 secondary antibody (Invitrogen) at 1:1,000 for 2 hours, followed by wash and mounting with Prolong Gold (Invitrogen). IgG 1 species-matched antibody was used for isotype negative control. An Olympus IX71 scope was used for fl uorescence microscopy.
Clonogenic and Soft Agar Assays
For 2-dimensional (2D) clonogenic assays, cells were plated at 5 × 10 3 cells per well in 6-well tissue culture-treated plates and grown for 72 hours in 2 mL basal medium. Drug treatments were carried out at 72 hours and then every other day for a total of 4 treatments for 2D colony assays or 6 treatments for soft agar assays, each time replenished with an additional 1 mL medium containing fresh drug(s). Cells were allowed to recover for 2 weeks for 2D colonies, or 3 to 4 weeks for soft agar. The 2D colonies were fi xed in ice-cold 100% methanol for 15 minutes and stained for 20 minutes with 0.05% crystal violet, followed by destaining with water. For soft agar, the base layer consisted of 1 mL 1.6% low-gelling temperature agarose (Sigma Aldrich; cat. no. A9414) combined with 1 mL 2× RPMI medium with 20% FBS and 2% P/S (2× RPMI complete). The top layer consisted of 750 μL 0.6% agarose combined with 750 μL 2× RPMI complete medium containing 1 × 10 4 cells per well in 6-well plate format. Colony spheres were fi xed and stained with 0.01% crystal violet [50 mL MeOH, 10 mL glacial acetic acid, 4 mL 0.5% crystal violet, 36 mL dH 2 0] for 2 hours at room temperature, followed by destaining with water. The 2D clonogenic plates were scanned with a VersaDoc Model 3000 imager (Bio-Rad) and Quantity One software. Soft agar plates were photographed. Both 2D and soft agar colonies were enumerated using ImageJ software version 1.46r.
Immunoblotting
Immunoblots were conducted with the following primary antibodies, all at 1:1,000: NRAS (cat. no. sc-31), GAPDH (sc-25778), and EGFR (sc-03; Santa Cruz Biotechnology); phospho-AKT (Ser473; cat. no. 4060), AKT 
RNA Interference
The NRAS siRNA ON-TARGET plus SMARTpool (Dharmacon) was used for in vitro knockdown experiments. Ten microliters of FuGENE HD transfection reagent (Promega) was added to 190 μL of basal media without P/S, mixed by inversion, and allowed to equilibrate for 10 minutes. In parallel, 10 μL siRNA was added to 190 μL of basal media without P/S at 500 nmol/L and combined 1:1 with the transfection reagent/basal media mixture, resuspended, and added to cells at 30% to 50% confl uence in 6-well plate format in 1,600 μL media (fi nal siRNA concentration, 50 nmol/L). Fresh siRNA/transfection reagent mixture was added again 24 hours later, as described above, and cells were collected for protein or fl ow cytometry after 96-hour total exposure to siRNA. Flavopiridol (0.1 μmol/L) was added 48 hours before protein or cell collection, where indicated.
Xenografts
A total of 5 × 10 6 cells were resuspended in basal medium and injected subcutaneously into both fl anks of 5-to 6-week-old NCr nude mice (Taconic). Tumors were grown until palpable at 200 mm 3 before treatments. Simvastatin was slowly dissolved in prewarmed PBS and delivered daily by oral gavage at 10 mg/kg. Flavopiridol was dissolved in prewarmed 0.1% saline solution and delivered intraperitoneally every other day. Tumors were measured by digital caliper every other day, and volume was estimated using the equation Volume = (width) 2 × length/2.
